Scarica l'app Stockscreener
0.178
3.99%
-0.0074
Dopo l'orario di chiusura:
.18
0.002
+1.12%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
Aptose Biosciences shareholders approve reverse stock split By Investing.com - Investing.com Canada
Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Increase in Short Interest - Defense World
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-JAN-2025. - Marketscreener.com
Aptose Biosciences faces Nasdaq delisting over share price - MSN
Aptose Biosciences faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Aptose Biosciences Inc. Files 8-K Report - Defense World
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
Aptose Biosciences Inc. Issues Regulation FD Disclosure in Recent Press Release - Defense World
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - The Manila Times
Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy - TipRanks
Aptose Launches TUSCANY Trial: Groundbreaking Triple Therapy for Untreated AML Patients - StockTitan
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences (NASDAQ: APTO) Announces Regulation FD DisclosureOn December 19, 2024, Aptose Biosciences Inc. issued a press release, providing detailed information on recent developments. The press release specified various financial results - Defense World
Aptose Announces Positive Decision by Nasdaq Hearings Panel - The Manila Times
Aptose gets Nasdaq extension to regain compliance - MSN
Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan
Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register
SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow
Tuspetinib shows promise in AML treatment, study finds By Investing.com - Investing.com UK
Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire
Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - Yahoo Finance
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - The Manila Times
Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada
Likelihood of Approval and Phase Transition Success Rate ModelTuspetinib in Chronic Myelomonocytic Leukemia (CMML) - GlobalData
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - The Manila Times
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan
Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register
Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):